FMA
GNCA

FNY Managed Accounts’s Genocea Biosciences, Inc. GNCA Stock Holding History

FNY Managed Accounts’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,719
Closed -$106K – 467
2016
Q1 		$106K Buy
+1,719
New +$54.6K 0.19% 94

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

FNY Managed Accounts's GNCA Position: Q2 2016 in Review

FNY Managed Accounts sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2016, closing a stake of 1,719 shares — an estimated $106K sold.

FNY Managed Accounts first reported a position in GNCA in Q1 2016 and held it in 1 quarter. The position peaked at $106K in Q1 2016. 57 funds tracked by Wall St. Rank hold GNCA as of Q2 2016.

  • FNY Managed Accounts reported no remaining Genocea Biosciences, Inc. position as of Q2 2016 after selling out during the quarter.
  • FNY Managed Accounts sold 1,719 Genocea Biosciences, Inc. shares in Q2 2016, an estimated $106K.
  • FNY Managed Accounts first reported a position in Genocea Biosciences, Inc. in Q1 2016 and held it in 1 quarter.
  • FNY Managed Accounts's Genocea Biosciences, Inc. position peaked at $106K in Q1 2016.
  • 57 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2016.

Based on FNY Managed Accounts's 13F filing for Q2 2016, filed 27 Jul 2016.